从轮环藤茎皮中提取的新型异黄酮对果糖诱导的实验性白内障的影响。
Effects of a novel isoflavonoid from the stem bark of Alstonia scholaris against fructose-induced experimental cataract.
机构信息
Department of Pharmacology, Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, India.
Department of Pharmacology, Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, India.
出版信息
J Integr Med. 2019 Sep;17(5):374-382. doi: 10.1016/j.joim.2019.06.002. Epub 2019 Jun 8.
OBJECTIVE
The present study investigated the anticataract activity of a novel isoflavonoid, isolated from stem bark of Alstonia scholaris, against fructose-induced experimental cataract.
METHODS
The bioactivity of fractions extracted from A. scholaris, an isolated isoflavonoid (ASII) was screened using in vitro (goat lens) and in vivo (albino rats) experimental cataract models. For the in vivo evaluation, albino rats (12-15 weeks old) were divided into five groups (n = 6). Group I (normal) received 0.3% carboxymethyl cellulose solution (10 mL/[kg·d], p.o.). Group II (control) received 10% (w/v) fructose solution in their drinking water. Groups III-V received ASII at three different doses, 0.1, 1.0 and 10 mg/(kg·d), concurrently with 10% (w/v) fructose solution. Treatment was given daily for 8 consecutive weeks. During the protocol, systolic blood pressure, diastolic blood pressure, blood glucose level and lenticular opacity were monitored at 2-week intervals. Pathophysiological markers (catalase, superoxide dismutase, glutathione peroxidase, reduced glutathione and malondialdehyde) in eye lenses were examined at the end of the 8-week treatment period.
RESULTS
The results of in vitro study showed that A. scholaris extract and the active fraction (A) reduced the lenticular opacity as compared to toxic control group. The in vivo study showed that 8-week administration of ASII (0.1, 1.0 and 10 mg/[kg·d], p.o.) led to significant reduction in blood pressure and blood glucose level and retarded the initiation and evolution of cataractogenesis, compared to the fructose-induced cataract model control. Additionally, ASII treatment led to significant improvement in lens antioxidants (catalase, superoxide dismutase, glutathione peroxidase and reduced glutathione) and decreased lens malondialdehyde, compared to the control group (group II).
CONCLUSION
Results revealed that administration of ASII played a crucial role in the reduction of cataract formation in diabetic and hypertensive models.
目的
本研究旨在探讨从夹竹桃科鸡骨常山茎皮中分离得到的一种新异黄酮对果糖诱导的实验性白内障的抗白内障活性。
方法
采用体外（山羊晶状体）和体内（白化大鼠）实验性白内障模型筛选从鸡骨常山提取的各馏分及分离得到的异黄酮（ASII）的生物活性。在体内评价中，将 12-15 周龄的白化大鼠分为 5 组（n=6）。第 I 组（正常）给予 0.3%羧甲基纤维素溶液（10mL/[kg·d]，po）。第 II 组（对照）给予饮用水中 10%（w/v）果糖溶液。第 III-V 组分别给予 ASII 三个不同剂量，0.1、1.0 和 10mg/（kg·d），同时给予 10%（w/v）果糖溶液。治疗每日进行，连续 8 周。在方案期间，每 2 周监测一次收缩压、舒张压、血糖水平和晶状体混浊度。在 8 周治疗期末，检查晶状体中的病理生理标志物（过氧化氢酶、超氧化物歧化酶、谷胱甘肽过氧化物酶、还原型谷胱甘肽和丙二醛）。
结果
体外研究结果表明，与毒性对照组相比，鸡骨常山提取物和活性馏分（A）降低了晶状体混浊度。体内研究表明，与果糖诱导的白内障模型对照组相比，8 周给予 ASII（0.1、1.0 和 10mg/[kg·d]，po）可显著降低血压和血糖水平，并延缓白内障形成的起始和进展。此外，与对照组（第 II 组）相比，ASII 治疗可显著改善晶状体抗氧化剂（过氧化氢酶、超氧化物歧化酶、谷胱甘肽过氧化物酶和还原型谷胱甘肽）并降低晶状体丙二醛。
结论
结果表明，ASII 的给药在糖尿病和高血压模型中减少白内障形成方面发挥了关键作用。
Zotero 插件